Disease modifying therapeutic strategies in Alzheimer's disease targeting the amyloid cascade

Current Neuropharmacology

Volumn 2, Issue 3, 2004, Pages 295-307

  Czech, Christian ^a   Adessi, Céline ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Alzheimer's disease; Amyloid beta peptide; Amyloid cascade hypothesis; Amyloid precursor protein; Disease modifying therapeutic

Indexed keywords

4 [2 [1 (4 CHLOROCINNAMYL) 4 PIPERAZINYL]ETHYL]BENZOIC ACID; ACETYLCHOLINE; ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHOLESTEROL; CHOLINESTERASE INHIBITOR; CLIOQUINOL; CYTOCHROME P450; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GLYCOSAMINOGLYCAN; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; L 411575; L 685458; LY 411575; MONOCLONAL ANTIBODY; MUSCARINIC M1 RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PEPSTATIN DERIVATIVE; PPI 1019; PPI 368; SIMVASTATIN; TALSACLIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; ALZHEIMER DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DETERIORATION; DEVELOPED COUNTRY; DISEASE COURSE; DRUG DESIGN; DRUG INDUSTRY; DRUG TARGETING; HUMAN; HYPOTHESIS; INHIBITION KINETICS; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; REVIEW; SIDE EFFECT; SYMPTOM;

EID: 3242739287     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159043359666     Document Type: Review

References (129)

1. Adessi, C., Frossard, M. J., Boissard, C., Fraga, S., Bieler, S., Ruckle, T., Vilbois, F., Robinson, S. M., Mutter, M., Banks, W. A., and Soto, C. (2003) Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem., 278, 13905-13911.
2. Adessi, C., and Soto, C. (2002) Beta-sheet breaker strategy for the treatment of Alzheimer's disease. Drug Development Reseach, 56, 184-193.
3. Adessi, C., and Soto, C. (2002) Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem., 9, 963-978.
4. Arbiser, J. L., Kraeft, S. K., van Leeuwen, R., Hurwitz, S. J., Selig, M., Dickersin, G. R., Flint, A., Byers, H. R., and Chen, L. B. (1998) Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Mol. Med., 4, 665-670.
5. Asai, M., Hattori, C., Szabo, B., Sasagawa, N., Maruyama, K., Tanuma, S., and Ishiura, S. (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem. Biophys. Res. Commun., 301, 231-235.
6. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee. M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., and Yednock, T. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 6, 916-919.
7. Buxbaum, J. D., Cullen, E. I., and Friedhoff, L. T. (2002) Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front. Biosci., 7, a50-59.
8. Chartier-Harlin, M. C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., and Mullan, M. (1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature, 353, 844-846.
9. Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y., Huang, X., Goldstein, L. E., Moir, R. D., Lim, J. T., Beyreuther, K., Zheng, H., Tanzi, R. E., Masters, C. L., and Bush, A. I. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 30, 665-676.
10. Cherny, R. A., Legg, J. T., McLean, C. A., Fairlie, D. P., Huang, X., Atwood, C. S., Beyreuther, K., Tanzi, R. E., Masters, C. L., Bush, A. I., and Li, Q. X. (1999) Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. J. Biol. Chem., 274, 23223-23228.
11. Chou, P. Y., and Fasman, G. D. (1978) Empirical predictions of protein conformation. Annu. Rev. Biochem., 47, 251-276.
12. Cordy, J. M., Hussain, I., Dingwall, C., Hooper, N. M., and Turner, A. J. (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA, 100, 11735-11740.
13. Czech, C., Tremp, G., and Pradier, L. (2000) Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. Prog. Neurobiol., 60, 363-384.
14. Dahlgren, K. N., Manelli, A. M., Stine, W. B. Jr., Baker, L. K., Krafft, G. A., and LaDu, M. J. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem., 277, 32046-32053.
15. De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., Goate, A., and Kopan, R. (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature, 398, 518-522.
16. De Strooper, B., and Konig, G. (1999) Alzheimer's disease. A firm base for drug development. Nature, 402, 471-472.
17. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., and Holtzman, D. M. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 98, 8850-8855.
18. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., and Holtzman, D. M. (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science, 295, 2264-2267.
19. Desdouits-Magnen, J., Desdouits, F., Takeda, S., Syu, L. J., Saltiel, A. R., Buxbaum, J. D., Czernik, A. J., Nairn, A. C., and Greengard, P. (1998) Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J. Neurochem., 70, 524-530.
20. Dewachter, I., van Dorpe, J., Spittaels, K., Tesseur, I., Van Den Haute, C., Moechars, D., and Van Leuven, F. (2000) Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp. Gerontol., 35, 831-841.
21. Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., and Paul, S. M. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci., 5, 452-457.
22. Dominguez, D. I., and De Strooper, B. (2002) Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends Pharmacol. Sci., 23, 324-330.
23. Dovey, H. F., John, V., Anderson, J. P., Chen, L. Z., de Saint Andrieu, P., Fang, L. Y., Freedman, S. B., Folmer, B., Goldbach, E., Holsztynska, E. J., Hu, K. L., Johnson-Wood, K. L., Kennedy, S. L., Kholodenko, D., Knops, J. E., Latimer, L. H., Lee, M., Liao, Z., Lieberburg, I. M., Motter, R. N., Mutter, L. C., Nietz, J., Quinn, K. P., Sacchi, K. L., Seubert, P. A., Shopp, G. M., Thorsett, E. D., Tung, J. S., Wu, J., Yang, S., Yin, C. T., Schenk, D. B., May, P. C., Altstiel, L. D., Bender, M. H., Boggs, L. N., Britton, T. C., Clemens, J. C., Czilli, D. L., Dieckman-McGinty, D. K., Droste, J. J., Fuson, K. S., Gitter, B. D., Hyslop, P. A., Johnstone, E. M., Li, W. Y., Little, S. P., Mabry, T. E., Miller, F. D., and Audia, J. E. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem., 76, 173-181.
24. Duff, K. (1999) Curing amyloidosis: will it work in humans? Trends Neurosci., 22, 485-486.
25. Etminan, M., Gill, S., and Samii, A. (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ, 327, 128.
26. Farzan, M., Schnitzler, C. E., Vasilieva, N., Leung, D., and Choe, H. (2000) BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc. Natl. Acad. Sci. USA, 97, 9712-9717.
27. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., Runz, H., Kuhl, S., Bertsch, T., von Bergmann, K., Hennerici, M., Beyreuther, K., and Hartmann, T. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta - amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 54, 905-913.
28. Findeis, M. A. (2002) Peptide inhibitors of beta amyloid aggregation. Curr. Top Med. Chem., 2, 417-423.
29. Fortini, M. E. (2002) Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat. Rev. Mol. Cell Biol., 3, 673-684.
30. Francis, R., McGrath, G., Zhang, J., Ruddy, D. A., Sym, M., Apfeld, J., Nicoll, M., Maxwell, M., Hai, B., Ellis, M. C., Parks, A. L., Xu, W., Li, J., Gurney, M., Myers, R. L., Himes, C. S., Hiebsch, R., Ruble, C., Nye, J. S., and Curtis, D. (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell, 3, 85-97.
31. Ghanta, J., Shen, C. L., Kiessling, L. L., and Murphy, R. M. (1996) A strategy for designing inhibitors of beta-amyloid toxicity. J. Biol. Chem., 271, 29525-29528.
32. Ghosh, A., Shin, D., Downs, B., Kolesch, G., Lin, X., Ermolieff, J., and Tang (2000) Desong of potent inhibitors for human brain memapsin 2 (beta-secretase). J. Am. Chem. Soc., 122, 3522-3523.
33. Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., Roques, P., Talbot, C., Pericak-Vance, M., Roses, A., Williamson, R., Rossor, M., Owen, M., and Hardy, J. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 349, 704-706.
34. Gowing, E., Roher, A. E., Woods, A. S., Cotter, R. J., Chaney, M., Little, S. P., and Ball, M. J. (1994) Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J. Biol. Chem., 269, 10987-10990.
35. Gruninger-Leitch, F., Schlatter, D., Kung, E., Nelbock, P., and Dobeli, H. (2002) Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J. Biol. Chem., 277, 4687-4693.
36. Halverson, K., Fraser, P. E., Kirschner, D. A., and Lansbury, P. T., Jr. (1990) Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry, 29, 2639-2644.
37. Hartmann, D., de Strooper, B., Serneels, L., Craessaerts, K., Herreman, A., Annaert, W., Umans, L., Lubke, T., Lena Illert, A., von Figura, K., and Saftig, P. (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum. Mol. Genet., 11, 2615-2624.
38. Helmuth, L. (2000) Neuroscience. An antibiotic to treat Alzheimer's? Science, 290, 1273-1274.
39. Hilbich, C., Kisters-Woike, B., Reed, J., Masters, C. L., and Beyreuther, K. (1992) Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J. Mol. Biol., 228, 460-473.
40. Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Muller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., Wollmer, M. A., Umbricht, D., de Quervain, D. J., Hofmann, M., Maddalena, A., Papassotiropoulos, A., and Nitsch, R. M. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 38, 547-554.
41. Hock, C., Maddalena, A., Raschig, A., Muller-Spahn, F., Eschweiler, G., Hager, K., Heuser, I., Hampel, H., Muller-Thomsen, T., Oertel, W., Wienrich, M., Signorell, A., Gonzalez-Agosti, C., and Nitsch, R. M. (2003) Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid, 10, 1-6.
42. Hom, R. K., Fang, L. Y., Mamo, S., Tung, J. S., Guinn, A. C., Walker, D. E., Davis, D. L., Gailunas, A. F., Thorsett, E. D., Sinha, S., Knops, J. E., Jewett, N. E., Anderson, J. P., and John, V. (2003) Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. J. Med. Chem., 46, 1799-1802.
43. Hong, L., Koelsch, G., Lin, X., Wu, S., Terzyan, S., Ghosh, A. K., Zhang, X. C., and Tang, J. (2000) Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science, 290, 150-153.
44. Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., Mount, H. T., Nixon, R. A., Mercken, M., Bergeron, C., Fraser, P. E., St George-Hyslop, P., and Westaway, D. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 408, 979-982.
45. Jarrett, J. T., and Lansbury, P. T., Jr. (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell, 73, 1055-1058.
46. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A. (2000) Statins and the risk of dementia. Lancet, 356, 1627-1631.
47. Kaether, C., Lammich, S., Edbauer, D., Ertl, M., Rietdorf, J., Capell, A., Steiner, H., and Haass, C. (2002) Presenilin-1 affects trafficking and processing of betaAPP and is targeted in a complex with nicastrin to the plasma membrane. J. Cell Biol., 158, 551-561.
48. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K., and Muller-Hill, B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature, 325, 733-736.
49. Kelly, J. W. (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol., 6, 11-17.
50. Kim, C. A., and Berg, J. M. (1993) Thermodynamic beta-sheet propensities measured using a zinc-finger host peptide. Nature, 362, 267-270.
51. Knowles, J., and Gromo, G. (2003) Target selection in drug discovery. Nature, 2, 63-69.
52. Kojro, E., Gimpl, G., Lammich, S., Marz, W., and Fahrenholz, F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Natl. Acad. Sci. USA, 98, 5815-5820.
53. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 95, 6448-6453.
54. Lansbury, P. T., Jr. (1997) Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease. Curr. Opin. Chem. Biol., 1, 260-267.
55. Lanz, T. A., Himes, C. S., Pallante, G., Adams, L., Yamazaki, S., Amore, B., and Merchant, K. M. (2003) The gamma-secretase inhibitor N-N-[3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharmacol. Exp. Ther., 305, 864-871.
56. LaVoie, M. J., Fraering, P. C., Ostaszewski, B. L., Ye, W., Kimberly, W. T., Wolfe, M. S., and Selkoe, D. J. (2003) Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J. Biol. Chem., 278, 37213-37222.
57. LaVoie, M. J., and Selkoe, D. J. (2003) The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J. Biol. Chem., 278, 34427-34437.
58. Lee, V. M. (2001) Abeta immunization: moving Abeta peptide from brain to blood. Proc. Natl. Acad. Sci. USA, 98, 8931-8932.
59. Li, Y. M., Xu, M., Lai, M. T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., Register, R. B., Sardana, M. K., Shearman, M. S., Smith, A. L., Shi, X. P., Yin, K. C., Shafer, J. A., and Gardell, S. J. (2000) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature, 405, 689-694.
60. Locatelli, S., Lutjohann, D., Schmidt, H. H., Otto, C., Beisiegel, U., and von Bergmann, K. (2002) Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol., 59, 213-216.
61. Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., and Russell, D. W. (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem., 278, 22980-22988.
62. Lutjohann, D., Papassotiropoulos, A., Bjorkhem, I., Locatelli, S., Bagli, M., Oehring, R. D., Schlegel, U., Jessen, F., Rao, M. L., von Bergmann, K., and Heun, R. (2000) Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid. Res., 41, 195-198.
63. Maillet, M., Robert, S. J., Cacquevel, M., Gastineau, M., Vivien, D., Bertoglio, J., Zugaza, J. L., Fischmeister, R., and Lezoualc'h, F. (2003) Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat. Cell Biol., 5, 633-639.
64. Mann, D. M. (1989) Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome. Neurobiol. Aging, 10, 397-399; discussion 412-394.
65. Marambaud, P., Wen, P. H., Dutt, A., Shioi, J., Takashima, A., Siman, R., and Robakis, N. K. (2003) A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell, 114, 635-645.
66. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA, 82, 4245-4249.
67. Mills, J., Laurent Charest, D., Lam, F., Beyreuther, K., Ida, N., Pelech, S. L., and Reiner, P. B. (1997) Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J. Neurosci., 17, 9415-9422.
68. Monsonego, A., and Weiner, H. L. (2003) Immunotherapeutic approaches to Alzheimer's disease. Science, 302, 834-838.
69. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., and Arendash, G. W. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408, 982-985.
70. Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., and Lannfelt, L. (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet., 1, 345-347.
71. Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., and Weller, R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 9, 448-452.
72. Nitsch, R. M., Slack, B. E., Wurtman, R. J., and Growdon, J. H. (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science, 258, 304-307.
73. Park, I. H., Hwang, E. M., Hong, H. S., Boo, J. H., Oh, S. S., Lee, J., Jung, M. W., Bang, O. Y., Kim, S. U., and Mook-Jung, I. (2003) Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol. Aging, 24, 637-643.
74. Permanne, B., Adessi, C., Saborio, G. P., Fraga, S., Frossard, M. J., Van Dorpe, J., Dewachter, I., Banks, W. A., Van Leuven, F., and Soto, C. (2002) Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J., 16, 860-862.
75. Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci., 13, 1676-1687.
76. Pradier, L., Carpentier, N., Delalonde, L., Clavel, N., Bock, M. D., Buee, L., Mercken, L., Tocque, B., and Czech, C. (1999) Mapping the APP/presenilin (PS) binding domains: the hydrophilic N-terminus of PS2 is sufficient for interaction with APP and can displace APP/PS1 interaction. Neurobiol. Dis., 6, 43-55.
77. Primakoff, P., and Myles, D. G. (2000) The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet., 16, 83-87.
78. Puglielli, L., Konopka, G., Pack-Chang, E., Ingano, L. A., Berezovska, O., Hyman, B. T., Chang, T. Y., Tanzi, R. E., and Kovacs, D. M. (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol., 3, 905-912.
79. Refolo, L. M., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., Duff, K., and Pappolla, M. A. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis., 7, 321-331.
80. Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M., Petanceska, S. S., and Duff, K. E. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis., 8, 890-899.
81. Runz, H., Rietdorf, J., Tomic, I., Bernard, M., Beyreuther, K., Pepperkok, R., and Hartmann, T. (2002) Inhibition of Intracellular Cholesterol transport alters Presenilin localization and Amyloid Precursor Protein processing in neural cells. J. Neurosci., 22, 1679-1689.
82. Saido, T. C., Iwatsubo, T., Mann, D. M., Shimada, H., Ihara, Y., and Kawashima, S. (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron. 14, 457-466.
83. Saunders, A., Kim, T.-W., and Tanyi, R. (1999) BACE maps to chromosome II and a BACE homolog, BACE2 reside in the obligate Downs syndrome region of chromosom 21. Science. 286, 1255a.
84. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177.
85. Selkoe, D. J. (1991) The molecular pathology of Alzheimer's disease. Neuron, 6, 487-498.
86. Selkoe, D. J., and Schenk, D. (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol., 43, 545-584.
87. Shearman, M. S., Better, D., Clarke, E. E., Lewis, H. D., Harrison, T., Hunt, P., Nadin, A., Smith, A. L., Stevenson, G., and Castro, J. L. (2000) L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry, 39, 8698-8704.
88. Sigurdsson, E. M., Permanne, B., Soto, C., Wisniewski, T., and Frangione, B. (2000) In vivo reversal of amyloid-beta lesions in rat brain. J. Neuropathol. Exp. Neurol., 59, 11-17.
89. Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., and Wisniewski, T. (2001) Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol., 159, 439-447.
90. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., and Simons, K. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA, 95, 6460-6464.
91. Sinha, S., Anderson, J., John, V., McConlogue, L., Basi, G., Thorsett, E., and Schenk, D. (2000) Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann. N. Y. Acad. Sci., 920, 206-208.
92. Solomon, B., Koppel, R., Frankel, D., and Hanan-Aharon, E. (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA, 94, 4109-4112.
93. Solomon, B., Koppel, R., Hanan, E., and Katzav, T. (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. USA, 93, 452-455.
94. Soto, C. (1999) Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol. Med. Today, 5, 343-350.
95. Soto, C., Branes, M. C., Alvarez, J., and Inestrosa, N. C. (1994) Structural determinants of the Alzheimer's amyloid beta-peptide. J. Neurochem., 63, 1191-1198.
96. Soto, C., Castano, E. M., Frangione, B., and Inestrosa, N. C. (1995) The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J. Biol. Chem., 270, 3063-3067.
97. Soto, C., Castano, E. M., Kumar, R. A., Beavis, R. C., and Frangione, B. (1995) Fibrillogenesis of synthetic amyloid-beta peptides is dependent on their initial secondary structure. Neurosci. Lett., 200, 105-108.
98. Soto, C., Ghiso, J., and Frangione, B. (1997) Alzheimer's amyloid beta aggregation is modulated by the interaction of multiple factors. Alzheimer's Research, 3, 215-222.
99. Soto, C., Kindy, M. S., Baumann, M., and Frangione, B. (1996) Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun., 226, 672-680.
100. Soto, C., Permanne, B., Van Leuven, F., Fraga, S., Frossard, M. J., Chacon, M., Banks, W. P., Inestrosa, N. C., and Adessi, C. (2003) Beta-sheet breaker peptide for the treatment of Alzheimer's disease. In 6th International Conference, AD/PD, Sevilla, Spain.
101. Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A.. Castano, F. M., and Frangione, B. (1998) Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med., 4, 822-826.
102. Sparks, D. L., Scheff, S. W., Hunsaker, J. C., 3rd, Liu, H., Landers, T., and Gross, D. R. (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol., 126, 88-94.
103. St George-Hyslop, P. H., and Westaway, D. A. (1999) Alzheimer's disease. Antibody clears senile plaques. Nature, 400, 116-117.
104. Steiner, H., Duff, K., Capell, A., Romig, H., Grim, M. G., Lincoln, S., Hardy, J., Yu, X., Picciano, M., Fechteler, K., Citron, M., Kopan, R., Pesold, B., Keck, S., Baader, M., Tomita, T., Iwatsubo, T., Baumeister, R., and Haass, C. (1999) A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J. Biol. Chem., 274, 28669-28673.
105. Suh, Y. H., and Checler, F. (2002) Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev., 54, 469-525.
106. Takahashi, Y., Hayashi, I., Tominari, Y., Rikimaru, K., Morohashi, Y., Kan, T., Natsugari, H., Fukuyama, T., Tomita, T., and Iwatsubo, T. (2003) Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J. Biol. Chem., 278, 18664-18670.
107. Teplow, D. B. (1998) Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid, 5, 121-142.
108. Terry, R. D. (1994) Neuropathological changes in Alzheimer disease. Prog. Brain Res., 101, 383-390.
109. Tian, G., Ghanekar, S. V., Aharony, D., Shenvi, A. B., Jacobs, R. T., Liu, X., and Greenberg, B. D. (2003) The mechanism of gamma-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. J. Biol. Chem., 278, 28968-28975.
110. Tjernberg, L. O., Naslund, J., Lindqvist, F., Johansson, J., Karlstrom, A. R., Thyberg, J., Terenius, L., and Nordstedt, C. (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem., 271, 8545-8548.
111. Tremblay, P., Yu, M., Aman, A., Paquette, J., Krzywkowski, P., Morissette, C., King, X., and Gervais, F. (2003) GAG mimetics as a therapeutic approach to AD and CAA: reduction of parenchymal and vascular amyloid deposition in APP transgenic mice. In 6th international conference AD/PD, Sevilla, Spain.
112. Tsuji, A., Saheki, A., Tamai, I., and Terasaki, T. (1993) Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J. Pharmacol. Exp. Ther., 267, 1085-1090.
113. Turner, P. R., O'Connor, K., Tate, W. P., and Abraham, W. C. (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol., 70, 1-32.
114. Vassar, R. (2002) Beta-secretase (BACE) as a drug target for Alzheimer's disease. Adv. Drug Deliv. Rev., 54, 1589-1602.
115. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Life, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286, 735-741.
116. Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., and Teplow, D. B. (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem., 274, 25945-25952.
117. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416, 535-539.
118. Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., and Teplow, D. B. (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem., 272, 22364-22372.
119. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Butter, T., Kang, D. E., Marquez-Sterling, N., Golde, T. E., and Koo, E. H. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 414, 212-216.
120. Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V., Fauq, A., Golde, T. E., and Koo, E. H. (2003) Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem., 278, 31831-31837.
121. Weiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Issazadeh, S., Hancock, W. W., and Selkoe, D. J. (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol., 48, 567-579.
122. Wolfe, M. S. (2002) Therapeutic strategies for Alzheimer's disease. Nat. Rev. Drug. Discov., 1, 859-866.
123. Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature, 398, 513-517.
124. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol., 57, 1439-1443.
125. Wood, S. J., Wetzel, R., Martin, J. D., and Hurle, M. R. (1995) Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry, 34, 724-730.
126. Xia, W., Zhang, J., Perez, R., Koo, E. H., and Selkoe, D. J. (1997) Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Proc. Natl. Acad. Sci. USA, 94, 8208-8213.
127. Xu, H., Sweeney, D., Greengard, P., and Gandy, S. (1996) Metabolism of Alzheimer beta-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free system. Proc. Natl. Acad. Sci. USA, 93, 4081-4084.
128. Yassin, M. S., Ekblom, J., Xilinas, M., Gottfries, C. G., and Oreland, L. (2000) Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J. Neurol. Sci., 173, 40-44.
129. Yu, G., Nishimura, M., Arawaka, S., Levitan, D., Zhang, L., Tandon, A., Song, Y. Q., Rogaeva, E., Chen, F., Kawarai, T., Supala, A., Levesque, L., Yu, H., Yang, D. S., Holmes, E., Milman, P., Liang, Y., Zhang, D. M., Xu, D. H., Sato, C., Rogaev, E., Smith, M., Janus, C., Zhang, Y., Aebersold, R., Fatter, L. S., Sorbi, S., Bruni, A., Fraser, P., and St George-Hyslop, P. (2000) Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature, 407, 48-54.